Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Cytokinetics has suggested aficamten has a competitive clinical profile to BMS' drug – pointing to strong data on exercise capacity, symptoms, biomarkers, cardiac structure and function ...

Stifel has initiated coverage of Cytokinetics (CYTK) with a buy rating, citing its drug aficamten, valuation and upcoming ...

Stifel initiated coverage of Cytokinetics (CYTK) with a Buy rating and $80 price target Cytokinetics “is an out-of-favor stock” following the ...

Cytokinetics has been a top biotech takeover candidate for some time, thanks to blockbuster speculation about its lead drug aficamten, but a $1 billion-plus set of financing deals shows it is ...

Aficamten is under clinical development by Cytokinetics and currently in Pre-Registration for Hypertrophic Cardiomyopathy. According to GlobalData, Pre-Registration drugs for Hypertrophic ...

Future Cardiol. 2013;9(5):697-709. It is extremely important to detect the presence and severity of LVOT obstruction from physical examination, as well as 2D and Doppler echocardiography. The LVOT ...

RBC Capital Mkts has recently initiated Cytokinetics, Inc. (CYTK) stock to Outperform rating, as announced on November 8, 2024, according to Finviz. Earlier, on August 13, 2024, Goldman had reduced ...

Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last three months and up 332% over the past 52 weeks.

After hours: January 17 at 6:11:16 PM EST ...